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Summary
Background Loss of arm function is a common problem after stroke. Robot-assisted training might improve arm 
function and activities of daily living. We compared the clinical effectiveness of robot-assisted training using the MIT-
Manus robotic gym with an enhanced upper limb therapy (EULT) programme based on repetitive functional task 
practice and with usual care.
Methods RATULS was a pragmatic, multicentre, randomised controlled trial done at four UK centres. Stroke patients 
aged at least 18 years with moderate or severe upper limb functional limitation, between 1 week and 5 years after their 
first stroke, were randomly assigned (1:1:1) to receive robot-assisted training, EULT, or usual care. Robot-assisted 
training and EULT were provided for 45 min, three times per week for 12 weeks. Randomisation was internet-based 
using permuted block sequences. Treatment allocation was masked from outcome assessors but not from participants 
or therapists. The primary outcome was upper limb function success (defined using the Action Research Arm Test 
[ARAT]) at 3 months. Analyses were done on an intention-to-treat basis. This study is registered with the ISRCTN 
registry, number ISRCTN69371850.
Findings Between April 14, 2014, and April 30, 2018, 770 participants were enrolled and randomly assigned to either 
robot-assisted training (n=257), EULT (n=259), or usual care (n=254). The primary outcome of ARAT success was 
achieved by 103 (44%) of 232 patients in the robot-assisted training group, 118 (50%) of 234 in the EULT group, and 
85 (42%) of 203 in the usual care group. Compared with usual care, robot-assisted training (adjusted odds ratio 
[aOR] 1·17 [98·3% CI 0·70–1·96]) and EULT (aOR 1·51 [0·90–2·51]) did not improve upper limb function; the effects 
of robot-assisted training did not differ from EULT (aOR 0·78 [0·48–1·27]). More participants in the robot-assisted 
training group (39 [15%] of 257) and EULT group (33 [13%] of 259) had serious adverse events than in the usual care 
group (20 [8%] of 254), but none were attributable to the intervention.
Interpretation Robot-assisted training and EULT did not improve upper limb function after stroke compared with 
usual care for patients with moderate or severe upper limb functional limitation. These results do not support the use 
of robot-assisted training as provided in this trial in routine clinical practice.
Funding National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Upper limb problems commonly occur after a stroke, 
comprising loss of movement, coordination, sensation, 
and dexterity, which lead to difficulties with activities of 
daily living (ADL) such as washing and dressing. About 
80% of people with acute stroke have upper limb motor 
impairment, and of those with reduced arm function 
early after stroke, 50% still have problems after 4 years.1 
The strongest predictor of recovery is severity of initial 
neurological deficit; patients with severe initial upper 
limb impairment are unlikely to recover arm function, 
with clear impact upon their quality of life. Patients 
report that loss of arm function is one of the most 
distressing long-term consequences of stroke. Improving 
upper limb function has been identified as a top 
ten research priority by stroke survivors, carers, and 
clinicians.2
How to optimise stroke patients’ upper limb recovery is 
unclear. Systematic reviews of therapy interventions 
suggest that patients benefit from therapy programmes 
in which they practise tasks directly rather than from 
interventions that focus on impairments.3,4 Intensity 
of therapy is also important; a Cochrane overview4 of 
systematic reviews found moderate quality Grading 
of Recommendations, Assessment, Development and 
Evaluations evidence that arm function after a stroke can 
be improved by the provision of at least 20 h of additional 
repetitive task training.
Robot-assisted arm training has shown promise for 
improving ADL, arm function, and arm muscle strength 
after stroke.5,6 However, studies vary in patient charac-
teristics, device used, duration and amount of training, 
control group, and outcome measures used. The benefits 
of robot-assisted arm training over conventional therapy 
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of the same frequency and duration have not been 
shown.7
This randomised controlled trial (RCT) aimed to 
establish whether robot-assisted training improved upper 
limb function after a stroke compared with an enhanced 
upper limb therapy (EULT) programme of the same 
frequency and duration and usual care alone. Robot-
assisted training and EULT involved repetitive task 
practice and were provided in addition to usual care.
Methods
Study design
RATULS was a three-group, pragmatic, multicentre RCT 
done at four National Health Service (NHS) centres in 
the UK. Each centre comprised a stroke service in an 
NHS hospital with an MIT-Manus robotic gym system 
(InMotion commercial version, Interactive Motion 
Technologies, Watertown, MA, USA), plus stroke services 
in adjacent NHS Trusts and community services. The 
trial protocol was approved by National Research Ethics 
Committee Sunderland (reference 13/NE/0274) and has 
been published.8
Participants
Study participants were adults (age ≥18 years) with 
moderate or severe upper limb functional limitation 
(Action Research Arm Test [ARAT] score 0–39)9 as a 
result of first-ever stroke that had occurred between 
1 week and 5 years before randomisation. Exclusion 
criteria were other notable impairment in the upper limb 
affected by stroke; other diagnosis that might interfere 
with rehabilitation or outcome assessments; previous 
use of the robotic gym system or other arm rehabilitation 
robot; participation in another upper limb rehabilitation 
trial; and previous enrolment in this study. Participants 
were recruited from stroke units, outpatient clinics, day 
hospitals, community rehabilitation services, local stroke 
clubs, and primary care. All participants provided written 
informed consent.
Randomisation and masking
Randomisation was done through a central independent 
web-based service hosted by Newcastle University Clinical 
Trials Unit. Participants were randomly assigned 1:1:1 to 
receive robot-assisted training, an EULT programme, or 
usual care using permuted block sequences stratified 
according to centre, time since stroke, and severity of 
upper limb functional limitation (ARAT score).9 The 
sequences were prepared by an independent statistician 
before the start of enrolment. Outcome data were 
intended to be collected by a masked researcher and any 
unmasking was recorded. Because of the nature of the 
Research in context
Evidence before this study
Robot-assisted training enables stroke patients with moderate 
or severe upper limb impairment to perform repetitive tasks in 
a highly consistent manner, tailored to their motor abilities. 
A 2018 Cochrane review (45 trials, 1619 participants) reported 
that electromechanical and robot-assisted arm training 
improved arm function (standardised mean difference 
[SMD] 0·32 [95% CI 0·18–0·46]) and activities of daily living 
(ADL) scores (0·31 [0·09–0·50]). The clinical importance of these 
differences is unclear and the results should be interpreted with 
caution because of study heterogeneity and variation in the 
quality of the included studies. Another review found no 
difference in any of these outcomes when robot-assisted 
training was compared with the same duration or intensity of 
conventional therapy. Theories of neuroplasticity and motor 
learning support an approach to rehabilitation based on 
repetitive practice of functional tasks. A 2016 Cochrane review 
(33 trials, 1853 participants) found that repetitive functional 
task practice for patients who had a stroke was associated with 
improved arm function (SMD 0·25 [95% CI 0·01–0·49]), 
hand function (0·25 [0·00–0·51]), and ADL (0·28 [0·10–0·45]). 
Again, the clinical importance of these findings is unclear.
Added value of this study
RATULS is the first multicentre trial with adequate statistical 
power to compare robot-assisted training with both an 
evidence-based therapy programme of the same frequency 
and duration (45 min face-to-face therapy, three times per 
week, for 12 weeks) and usual care. We found no significant 
difference in our primary outcome of upper limb function at 
3 months between stroke patients treated with robot-assisted 
training, an enhanced upper limb therapy programme (EULT), 
or usual care. Although some improvements for robot-assisted 
training were observed in upper limb impairment compared 
with usual care, these did not translate into improvement in 
upper limb function or ADL. EULT resulted in less upper limb 
impairment, better mobility, and better ADL at 3 months 
compared with usual care. Furthermore, EULT was superior to 
robot-assisted training for ADL at 3 months.
Implications of all the available evidence
The results of the RATULS trial do not support the routine use of 
robot-assisted training (MIT-Manus robotic gym) for patients 
with moderate or severe upper limb functional limitation 
resulting from stroke. Our findings will inform guidelines about 
the use of robot-assisted training and EULT in clinical practice. 
Further research is needed to find ways to translate the 
improvements in upper limb impairment seen with 
robot-assisted training into improvements in upper limb function 
and ADL. This might involve combining robot-assisted training 
with more functionally orientated therapy strategies. The RATULS 
trial provides evidence of the potential benefit of EULT, although 
as delivered in this trial, it is unlikely to be cost-effective. 
Innovations to make enhanced rehabilitation programmes more 
clinically effective and cost-effective are needed.
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intervention, patients and therapists could not be masked 
to the allocated treatment.
Procedures
Robot-assisted training and EULT programmes were 
delivered at the same frequency and duration: 45 min of 
face-to-face therapy, three times per week for 12 weeks. 
The same therapists and therapy assistants delivered 
both interventions at each centre. A detailed description 
of robot-assisted training and EULT using the Template 
for Intervention Description and Replication checklist 
is available.8 Robot-assisted training and EULT were 
delivered in addition to usual post-stroke care.
The robot-assisted training programme integrated 
training with all three modules of the MIT-Manus robotic 
gym (shoulder–elbow module, wrist module, hand 
module integrated on to the shoulder–elbow module). 
The EULT programme was designed to reflect best 
practice using repetitive functional task practice to work 
towards participant-centred goals.10,11 Therapists recorded 
data on the content of EULT sessions; the MIT-Manus 
robotic gym recorded data on the robot-assisted training 
sessions content.
Participants assigned to usual care received usual NHS 
care, which was provided by their local clinical service. The 
English national quality standard is that patients with 
stroke should be offered a minimum of 45 min of each 
appropriate therapy that is required, for a minimum of 
5 days per week, at a level that enables the patient to meet 
their rehabilitation goals for as long as they are continuing 
to benefit from therapy and as long as they are able to 
tolerate it. Many stroke units achieve this target for 
physiotherapy and occupational therapy, but considerable 
variation exists in service provision after discharge.12 
Participants in all three groups received an arm reha-
bilitation therapy log to record any upper limb rehabilitation 
received during the trial and any self-practice arm exercises 
done. The schedule of enrolment, inter ventions, and 
assessments can be found in the protocol.8
Assessments included the ARAT,9,13 which assesses 
upper limb function by scoring the ability to complete a 
range of functional tasks within four subscales (grasp, 
grip, pinch, and gross movement), with a total score from 
zero (no function) to 57 (normal function); Fugl–Meyer 
assessment (FMA);13,14 Barthel ADL Index;15 Stroke Impact 
Scale (SIS), version 3.0;16 and measurement of upper limb 
pain on a numerical rating scale (score 0–10). For all the 
scores except the upper limb pain scale, a higher score 
denotes better performance. The total upper extremity 
FMA scale assesses upper limb impairment by incor-
porating the motor, sensory, range of motion, and joint 
pain subscales (score 0–126). The FMA motor subscale is 
frequently used as a primary outcome in trials of robot-
assisted training (score 0–66). The Barthel ADL Index 
consists of ten activities, together scored from 0 to 20. 
The SIS is a self-completion, stroke-specific questionnaire 
to measure quality of life. There are nine dimensions 
(strength, hand function, mobility, ADL, emotion, 
memory, com munication, social participation, and stroke 
recovery). The dimension scores range from 0 to 100. All 
adverse events and serious adverse events were recorded 
in accordance with National Research Ethics Service 
Committee guidance for trials that are not assessing an 
investigational medicinal product.
Quality-adjusted life-years (QALYs) were derived from 
participant responses to the EQ-5D-5L17 questionnaire, 
which was completed at baseline, 3 months, and 6 months. 
Utility values were estimated from the responses using 
health state utility scores based on the UK population 
tariff18,19 and mapped back to the EQ-5D-3L valuation set.20 
Costs incurred by the NHS and Personal Social Services 
were collected via resource utilisation questionnaires, 
completed at baseline and 6 months.
Outcomes
The primary outcome was upper limb function success 
(defined using ARAT)9,13 at 3 months after random-
isation—ie, at the end of the intervention period. The 
definition of success differed depending on baseline 
severity: baseline ARAT score 0–7 required an improve-
ment of 3 points or more; baseline ARAT 8–13 required 
an improvement of 4 points or more; baseline ARAT 14–19 
required an improvement of 5 points or more; baseline 
ARAT 20–39 required an improvement of 6 points or 
more. A stepped approach was used, because although the 
minimal clinically important difference (MCID) for the 
ARAT is 10% of its range (6 points), a smaller treatment 
effect might still be clinically beneficial for those with 
severely reduced initial upper limb function, who are 
likely to improve less than those with more moderate 
reductions in function.
Secondary outcomes were upper limb function 
(ARAT)9,13 success at 6 months; ARAT score; upper limb 
impairment (FMA);13,14 ADL (Barthel ADL Index);15 quality 
of life (SIS, version 3.0);16 and upper limb pain (numerical 
rating scale). We also did economic analysis using data 
from resource utilisation questionnaires at baseline and 
6 months and the EQ-5D-5L at baseline, 3 months, and 
6 months.
Statistical analysis
The target sample size was 762 participants (254 par tici -
pants per group). Responses from 216 par ticipants in each 
group were required to provide 80% power (significance 
level of 1·7% because of multiple comparisons) to detect a 
15% difference in successful outcome between each of the 
three pairs of treatments (robot-assisted training, EULT, 
and usual care). The baseline estimate of success was 
estimated as 30% from the BoTULS trial11 and a difference 
between 30% and 45% corresponds to an odds ratio 
(OR) of 1·9. The sample size requirement was increased 
from 720 after protocol publication to allow for 15% rather 
than 10% attrition. Reasons for loss from the trial were 
recorded.
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The primary outcome of upper limb function success 
at 3 months is reported descriptively by group and overall 
as a proportion. Logistic regression was used to compare 
success between the three groups at 3 months, adjusting 
for time since stroke, baseline ARAT score, and centre. 
We considered the possibility of partial nesting due to 
participants sharing therapists in the robot-assisted 
training and EULT groups but not in the usual care 
group. This did not change the model estimates or 
improve model fit and so the simpler models without 
partial nesting were used. The secondary outcomes of 
success at 6 months and binary coding of ARAT subscales 
(appendix) were analysed as for the primary outcome. All 
analyses were done in the intention-to-treat (ITT) 
population of all participants, in the group to which they 
were assigned, who did not have missing data after 
simple imputation. Preplanned sensitivity analyses were 
done for ARAT success at 3 months and 6 months. 
The first sensitivity analysis excluded participants 
who attended their outcome assessment outside of the 
3 month ± 14 days, and 6 month ± 28 days windows. The 
second sensitivity analysis excluded participants with an 
ARAT score of zero at baseline. In a per-protocol analysis, 
we compared ARAT success at 3 months and 6 months 
for robot-assisted training versus EULT for participants 
who had attended at least 20 therapy sessions.
All numerical secondary outcomes were reported at 
baseline, 3 months, and 6 months descriptively by group 
as mean (SD). These secondary outcomes were analysed 
separately at 3 months and 6 months using linear 
regression adjusting for time since stroke, baseline score, 
and centre. The baseline score used to adjust the analysis 
was the same scale for that outcome—eg, baseline ARAT 
was used in the model for ARAT at follow-up. Bias-
corrected and accelerated CIs (100 000 bootstrap intervals) 
have been presented for all numerical secondary 
outcomes because of the distribution of the data. Three 
preplanned subgroup analyses explored the relationship 
between ARAT score at 3 months and centre, time since 
stroke (<3 months, 3–12 months, and >12 months), and 
baseline ARAT scores (0, 1–7, 8–13, 14–19, and 20–39).
Simple imputation was used in the calculation of the 
scales.21 Missing values contributing to a scale or subscale 
total were calculated using the median value of the 
respondent-specific completed responses on the rest of 
the scale or subscale to replace missing items, if no more 
than 20% of items were missing. The exception was the 
SIS, where we used the scale developers’ rules (for a 
particular participant, if <50% of items are missing in 
a dimension then the mean of the non-missing items 
is used in the formula for the final score; final 
score=25 × [mean of non-missing items–1]). For all 
analyses, the best fitting transformation of time since 
stroke was chosen on the basis of a significant reduction 
in model deviance. The coverage of the CIs was adjusted 
to account for the three paired comparisons between the 
groups. Because the study was powered on a significance 
level of 1·7%, we report 98·3% CIs. All CIs beyond 
the primary outcome were exploratory because no allow-
ance was made for multiplicity of outcomes. Statistical 
analyses were done using Stata, version 14. Independent 
trial steering and data monitoring committees had 
oversight throughout the trial and convened annually. 
A cost-utility analysis was done to assess the incremental 
cost per QALY gained. The analysis took the perspective 
of the NHS and Personal Social Services. The incremental 
cost per gained QALY for each participant at 6 months 
was calculated using the seemingly unrelated regression 
modelling method (sureg) in the adjusted cost-utility 
analysis.22 This method ensured that any imbalance 
between groups at baseline was not reflected in the 
estimated costs and QALYs. The covariates included in 
the regression analysis were centre, baseline ARAT score, 
time since stroke, baseline costs, and baseline utility 
score. To account for uncertainty in the cost-effectiveness 
results, a non-parametric bootstrap technique (involving 
1000 replications with replacement) was used as part of 
a stochastic sensitivity analysis.23 All health economics 
Figure 1: Trial profile
All participants assigned to intervention groups began their trial intervention. Reasons for withdrawals and missed 
assessments at 3 months and 6 months are in the appendix. 
254 assigned to usual care  
31 withdrew 
223 on study at 3 months 
16 did not have 
3-month 
assessment  
207 had 3-month 
assessment 
9 withdrew
214 on study at 6 months 
190 had 6-month 
assessment  
24 did not have 
6-month 
assessment 
259 assigned to enhanced 
upper limb therapy  
246 on study at 3 months 
770 enrolled
10 did not have 
3-month 
assessment  
8 withdrew
2 died 
236 on study at 6 months 
222 had 6-month 
assessment 
257 assigned to robot-
assisted training   
17 withdrew
1 died
12 withdrew
1 died
239 on study at 3 months 
6 did not have 
3-month 
assessment 
233 had 3-month 
assessment
236 had 3-month 
assessment
5 withdrew
234 on study at 6 months 
223 had 6-month 
assessment  
11 did not have 
6-month 
assessment 
14 did not have 
6-month 
assessment 
See Online for appendix
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analyses were done using Stata, version 15. The trial 
is registered with the ISRCTN registry, number 
ISRCTN69371850.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between April 14, 2014, and April 30, 2018, 770 partici-
pants were enrolled and randomly assigned to either 
robot-assisted training (n=257), EULT (n=259), or usual 
care (n=254; figure 1). Two participants who did not have 
a final diagnosis of stroke were withdrawn before the 
3-month assessment (one in the robot-assisted training 
group and one in the usual care group; appendix). Of the 
770 participants, 676 (88%) attended a 3-month asses-
sment and 635 (82%) attended a 6-month assessment. 
Seven participants did not complete the ARAT at their 
3-month assessment but were kept on study. Reasons why 
assessments were not done are shown in the appendix.
Baseline demographics and stroke characteristics 
were balanced between the groups at baseline (table 1). 
The mean age of participants was 61 (SD 14) years and 
468 (61%) were men. The median time from stroke 
to randomisation was 240 days (IQR 109–549) and 
participants had a mean ARAT score of 8·4 (SD 11·8), 
mean FMA motor score of 18·1 (SD 13·7) and mean 
Barthel ADL Index of 14·4 (SD 3·9).
Robot-assisted training participants attended a median 
of 35 (IQR 31 to 36) of the 36 sessions and EULT 
participants attended a median of 34 (IQR 29 to 36) of the 
36 sessions. The median duration of face-to-face therapy 
for each attended session was 41 min (IQR 35 to 47) for 
robot-assisted training and 45 min (IQR 45 to 45) 
for EULT. The median total duration of therapy per 
participant over the 12-week intervention was 23 h 28 min 
(IQR 18 h 53 min to 25 h 46 min) for robot-assisted 
training and 24 h 40 min (IQR 20 h 24 min to 26 h 15 min) 
for EULT. The appendix shows intervention fidelity.
669 participants were included in the primary outcome 
analysis (232 in the robot-assisted training group; 234 in 
the EULT group; and 203 in the usual care group). At 
3 months, 103 (44%) of 232 patients in the robot-assisted 
training group, 118 (50%) of 234 in the EULT group, and 
85 (42%) of 203 in the usual care group achieved upper 
limb functional recovery success (table 2; figure 2A). 
ARAT success was not significantly different for robot-
assisted training versus EULT (adjusted odds ratio 
[aOR] 0·78 [98·3% CI 0·48–1·27]) or usual care (aOR 1·17 
[0·70–1·96]) at 3 months (figure 2B). Similarly, comparison 
of EULT versus usual care showed no significant dif-
ference (aOR 1·51 [0·90–2·51]). At 6 months, 103 (47%) of 
221 in the robot-assisted training group, 118 (54%) of 
218 in the EULT group, and 81 (44%) of 185 in the usual 
care group achieved upper limb functional recovery 
success. Per-protocol and sensitivity analyses were con-
sistent with the ITT analysis (table 2).
ARAT scores were similar between the robot-assisted 
training and usual care groups at 3 months and 6 months 
(figure 2C, D). Robot-assisted training participants had 
less upper limb impairment on the FMA motor subscale 
than usual care participants at 3 months (adjusted mean 
difference 2·79 [98·3% CI 0·66–5·01]) and the difference 
was sustained at 6 months (adjusted mean difference 
Robot-assisted 
training (n=257)
Enhanced upper limb 
therapy (n=259)
Usual care  
(n=254)
Gender
Female 101 (39%) 100 (39%) 101 (40%)
Male 156 (61%) 159 (61%) 153 (60%)
Age at randomisation, years 59·9 (13·5) 59·4 (14·3) 62·5 (12·5)
Time from stroke to 
randomisation, days
233 (102–549) 258 (115–546) 242 (107–549)
Time from stroke to randomisation, months
<3 57 (22%) 46 (18%) 58 (23%)
3–12 105 (41%) 117 (45%) 106 (42%)
>12 95 (37%) 96 (37%) 90 (35%)
Stroke type
Cerebral infarction 197 (77%) 202 (78%) 214 (84%)
Primary intracerebral 
haemorrhage
58 (23%) 56 (22%) 38 (15%)
Subarachnoid haemorrhage 2 (1%) 1 (<1%) 2 (1%)
National Institute of Health Stroke 
Scale total score*
5·6 (3·2) 5·7 (3·2) 5·8 (3·2)
Arm affected by the stroke
Right 112 (44%) 116 (45%) 113 (44%)
Left 145 (56%) 143 (55%) 141 (56%)
Handedness*
Right 221 (87%) 223 (86%) 228 (90%)
Left 34 (13%) 35 (14%) 25 (10%)
Ambidextrous 0 1 (<1%) 1 (<1%)
Action Research Arm Test†
Mean (SD) 8·5 (11·9) 8·7 (11·9) 8·1 (11·5)
Median (IQR) 3·0 (0·0–11·5) 3·0 (0·0–13·0) 3·0 (0·0–11·0)
Score 0–7 178 (70%) 175 (68%) 173 (68%)
Score 8–13 18 (7%) 22 (8%) 23 (9%)
Score 14–19 13 (5%) 9 (3%) 13 (5%)
Score 20–39 47 (18%) 53 (20%) 45 (18%)
Fugl–Meyer assessment
Motor score* 18·0 (13·1) 18·2 (14·1) 18·2 (13·9)
Total upper extremity score‡ 68·9 (16·5) 69·0 (17·9) 68·9 (17·4)
Barthel ADL Index* 14·5 (3·8) 14·3 (4·0) 14·4 (3·9)
Numerical pain scale§ 2·9 (3·2) 2·7 (3·0) 2·6 (3·1)
Data are n (%), mean (SD), or median (IQR). ADL=activities of daily living. *Total number of patients was 255 in the 
robot-assisted training group. †Total number of patients was 256 in the robot-assisted training group. ‡Total number 
of patients was 254 in the robot-assisted training group. §Total number of patients was 253 in the robot-assisted 
training group. 
Table 1: Baseline demographics and clinical characteristics by randomisation group in the 
intention-to-treat population
Articles
56 www.thelancet.com   Vol 394   July 6, 2019
2·54 [0·07–5·06]; table 3; figure 2E, F; MCID 4 points for 
acute stroke patients24 and 5·25 points for chronic stroke 
patients25). All other differences between robot-assisted 
training and usual care were non-significant. The 
analysis of the ARAT subscales and the descriptive 
statistics for the remaining secondary outcomes (FMA 
[range of motion and sensory subscales] and SIS 
[strength, emotion, memory, communication, and stroke 
recovery]) are in the appendix.
Participants who had robot-assisted training performed 
less well in the ADL tests at 3 months than those allocated 
to EULT (table 2): Barthel ADL Index adjusted mean 
difference –0·51 (98·3% –1·02 to –0·01; MCID 1·85)25 and 
SIS ADL adjusted mean difference –4·81 (–9·48 to –0·12; 
MCID 5·9).25 Other measures were not different between 
the robot-assisted training and EULT groups.
Compared with participants who received usual care, 
EULT patients had less upper limb impairment on the 
FMA total score at 3 months (adjusted mean difference 
3·66 [98·3% CI 0·52–6·84]) and FMA motor subscale 
score (adjusted mean difference 2·96 [0·86–5·02]; 
table 3; MCID 4 for patients with acute stroke and 5·25 
for those with chronic stroke). Participants who received 
EULT had better upper limb function than those who 
had usual care in terms of ARAT total score (adjusted 
mean difference 2·54 [0·02–5·14]; figure 2D; table 3; 
MCID 6) at 3 months. Participants who had EULT scored 
higher on the Barthel ADL Index than those who had 
usual care (adjusted mean difference 0·70 [0·16–1·25] at 
3 months and 0·88 [0·29–1·48] at 6 months; MCID 1·85). 
Compared with usual care, patients who had EULT per-
formed better on SIS hand function (7·93 [2·24–13·51]; 
MCID 17·8), mobility (5·81 [0·45–11·20]; MCID 4·5), 
and ADL (5·55 [0·87–10·21]; MCID 5·9) at 3 months. 
No significant differences were recorded in the pain 
numerical rating scale tests.
The outcome assessors reported that they were 
unmasked for 50 (21%) of 233 participants at 3 months 
and 39 (17%) of 223 at 6 months in the robot-assisted 
training group, 26 (11%) of 236 participants at 3 months 
and 25 (11%) of 220 at 6 months in the EULT group, and 
25 (12%) of 207 at 3 months and 24 (13%) of 190 at 
6 months in the usual care group.
43 serious adverse events were reported for 39 par-
ticipants in the robot-assisted training group, 42 were 
reported for 33 participants in the EULT group, and 
29 were reported for 20 participants in the usual care 
group (appendix). None of the serious adverse events 
were related to a trial intervention. The median number 
of serious adverse events was zero (IQR 0–0) across all 
three groups. More serious adverse events occurred in the 
robot-assisted training group than in the usual care group 
(Mann-Whitney U test p=0·013), but other groups had 
similar numbers (robot-assisted training vs EULT p=0·45; 
EULT vs usual care p=0·08). These differences are 
probably due to a reporting bias, because those in the 
intervention groups had regular contact with clinical 
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teams—eg, six serious adverse events were reported for 
robot-assisted training participants by the local principal 
investigator, which did not result in hospitalisation or 
death.
There was no significant difference between the groups 
for mean ARAT score at 3 months within the prespecified 
subgroups of centre, time since stroke, or baseline ARAT 
score, although the 98·3% CIs were wide as expected 
because of the reduced sample size of the subgroups 
(appendix).
The unadjusted results of the economic analysis suggest 
that, on average, usual care was the least costly option at 
6 months (£3785 per participant) with robot-assisted 
training being the most costly (£5387 per participant; 
table 4). The average cost of EULT per participant was 
£4451; however, EULT had higher QALYs (0·229) than 
usual care (0·212) or robot-assisted training (0·212) at 
6 months. The incremental cost per QALY at 6 months for 
participants in the EULT group compared with those in the 
usual care group was £74 100, with a 19% chance of being 
cost-effective at the £20 000 willingness to pay threshold. 
Throughout the analysis, results suggested that robot-
assisted training was more costly than usual care and 
EULT, and was no more effective than EULT or usual care.
Discussion
We found no difference in upper limb function, defined 
as ARAT success, between stroke patients treated with 
robot-assisted training using the MIT-Manus robotic 
gym, a EULT programme, or usual care. All groups 
improved on this measure from baseline to 3 months, 
which was maintained at 6 months. Some differences in 
secondary outcomes suggest potential benefits for EULT 
and robot-assisted training that might have implications 
for clinical practice and future research. We found no 
safety concerns for either intervention. Neither robot-
assisted training nor EULT, when delivered with a one-to-
one patient-to-therapist ratio, would be considered 
cost-effective at the UK current level of willingness to pay 
per QALY (£20 000–30 000).
Of the many preplanned comparisons of the secondary 
outcomes, some indicated differences that are likely to be 
clinically important, because the MCID is within the 
98·3% CI. Robot-assisted training improved upper limb 
impairment as measured by the FMA motor subscale at 
3 months compared with usual care and this difference 
Figure 2: ARAT success, total ARAT score, and Fugl–Meyer motor score at 
baseline, 3 months, and 6 months
(A) Proportion of patients achieving ARAT success. (B) Pair-wise comparison of 
group success. (C) ARAT total score. (D) Pair-wise comparison of ARAT total 
score. (E) Fugl–Meyer motor score. (F) Pair-wise comparison of Fugl–Meyer 
motor score. In (C) and (E), the horizontal black line is the median, the box is 
the IQR, and whiskers extend to the closest value within the upper or lower 
quartile ± 1·5 multiplied by the IQR; the black dots are any values outside of this 
range. ARAT=Action Research Arm Test. EULT=enhanced upper limb therapy. 
RT=robot-assisted training. UC=usual care. 
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was maintained at 6 months. However, this improvement 
did not translate into improvement in either upper 
limb function or ADL. Indeed, robot-assisted training 
participants did less well in ADL at 3 months than those 
who received EULT. EULT led to improvements in upper 
limb impairment, mobility, and ADL compared with usual 
care at 3 months. No clinically important differences were 
found between EULT and usual care or robot-assisted 
training and EULT at 6 months on any outcome measure.
Although there was no significant difference between 
EULT and usual care in ARAT success, the absolute 
difference was 8% at 3 months and 10% at 6 months in 
favour of EULT. This difference might be considered 
important by some patients and clinicians, but the trial 
did not have the statistical power to detect a difference of 
this size.
The RATULS trial has a number of strengths and 
weaknesses. The risk of bias was low. As the study 
progressed, we abandoned the screening log because this 
became a disincentive for clinical teams to refer potential 
participants. Randomisation was by an independent 
service with allocation concealment. The outcome 
measures are widely used in stroke rehabilitation trials 
and have been shown to be valid, reliable, and sensitive 
to change.26 However, the primary outcome, derived from 
the ARAT, was developed specifically for the RATULS 
trial and further validation is needed. All outcomes were 
analysed according to statistical and health economic 
analysis plans. There were low levels of missing data for 
all assessments. Overall attrition rates were acceptable 
but were higher in the usual care group (20%) than in the 
robot-assisted training and EULT groups (both 10%), and 
differential attrition is a potential source of bias. Most of 
the withdrawals before 3 months in usual care were due 
to disappointment with treatment allocation.
There was robust development of robot-assisted train-
ing and EULT programmes, and efforts to promote 
fidelity. Robot-assisted training was compared to an upper 
limb therapy programme of the same frequency and 
duration based on best evidence and best practice. Experts 
in both robot-assisted training and EULT were involved 
in designing and delivering the training programmes. 
Both interventions have been described according to the 
Template for Intervention Description and Replication, 
enabling them to be replicated in further research or 
clinical practice.8 Robot-assisted training was provided as 
it would be in clinical practice, while EULT was provided 
as a centralised rather than a local service for logistical 
reasons. Intervention delivery was monitored throughout 
the trial with high levels of compliance.
RATULS was a pragmatic trial and therefore usual 
care was chosen as a comparator. Obtaining accurate 
information about the usual care that patients receive is a 
challenge for this type of study and the assumption that 
usual care is uniformly provided is rarely true. Although 
UK guidelines suggest the amount of therapy that a 
stroke patient should receive, they refer to contact time 
with a therapist rather than specifying the focus or 
intensity.27 Disappointment about group allocation might 
have resulted in some usual care participants seeking or 
being provided with additional therapy, or increasing the 
amount of self-practice exercises they did, thereby 
introducing a competitive therapy bias. We did consider 
offering either robot-assisted training or EULT to usual 
care participants after the 6-month outcome assessment, 
but this was not feasible.
The 2018 Cochrane systematic review of electro-
mechanical and robot-assisted arm training (45 trials, 
1619 participants) reported significantly improved ADL 
scores (standardised mean difference [SMD] 0·31 
[95% CI 0·09–0·50] and arm function (SMD 0·32 
[95% CI 0·18–0·46]) at the end of the intervention period.5 
Although this review described improvement in arm 
function, the FMA motor subscale, a measure of upper 
limb impairment, was reported as the most commonly 
used arm function outcome measure.
The robot-assisted training programme was provided 
at the same frequency and duration as intended in the 
Unadjusted mean 
cost (98·3% CI)
Unadjusted mean 
QALYs (98·3% CI)
Adjusted* incremental 
QALY (98·3% CI)
Adjusted* 
incremental costs 
(98·3% CI)
Adjusted incremental 
cost-effectiveness 
ratio
Probability that each therapy is cost effective 
at different willingness to pay thresholds†
£0 £10 000 £20 000 £30 000 £50 000
Robot-assisted 
training
£5387 (4777 to 5996) 0·212 (0·195 to 0·229) ·· ·· More expensive and 
less effective than EULT 
in both adjusted and 
unadjusted analyses
0% 0% 0% 0% 0%
Enhanced upper 
limb therapy
£4451 (3548 to 5354) 0·229 (0·213 to 0·244) 0·010 (–0·005 to 0·025) 741 (–461 to 1943) £74 100 10% 15% 19% 26% 38%
Usual care £3785 (2801 to 4770) 0·212 (0·194 to 0·230) ·· ·· ·· 90% 85% 81% 74% 62%
Numbers of patients included in analyses were 178 in the usual care group, 259 in the EULT group, and 257 in the robot-assisted training group for the unadjusted cost calculation; 254 in the usual care group, 
259 in the EULT group, and 257 in the robot-assisted training group for the unadjusted QALY calculation; and 171 in the usual care group, 254 in the EULT group, and 247 in the robot-assisted training group for 
the adjusted analyses. EULT=enhanced upper limb therapy. QALY=quality-adjusted life-year. *Adjusted analysis done using the seemingly unrelated regression (sureg) function on STATA, version 15; adjusted for 
centre, baseline ARAT score, time since stroke, baseline costs, and baseline utility score; performed for the comparison between usual care and EULT as the next best alternative. †The probabilistic sensitivity 
analysis includes all three therapies and was done for different threshold values of society’s willingness to pay per QALY (£0, £10 000, £20 000, £30 000, and £50 000).
Table 4: Results from base-case and probabilistic cost-utility analysis for usual care, EULT, and robot-assisted training
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VA Robotics Trial,28 which also assessed the MIT-Manus 
robotic gym. The VA Robotics Trial also found that robot-
assisted training improved upper limb impairment 
(FMA motor subscale) compared with usual care, but the 
impairment advantage did translate into significant 
upper limb functional improvements (Wolf Motor 
Function Test) and benefit in the SIS.28 The intensive 
comparative therapy in the VA Robotics trial sought to 
replicate the form and intensity of upper limb movements 
provided by MIT-Manus, and there were no significant 
differences between this and the robot-assisted training 
group. A strength of the RATULS trial is that robot-
assisted training was compared to an upper limb therapy 
programme, based on best evidence and best practice, of 
the same frequency and duration. The VA Robotics Trial 
reported that the average total cost of treatment over the 
intervention period was US$5152 for robot-assisted 
training and $7382 for intensive comparison therapy 
(p=0·001). In the VA Robotics Trial, the base-case analysis 
assumed that the MIT-Manus robotic gym was used by 
two patients simultaneously. At 36 weeks, the total 
health-care costs were similar for all three groups.29 The 
REM-AVC trial30 assigned participants to receive robot-
assisted training with an Armeo Spring device or self-
rehabilitation of the same frequency and duration, and 
found no difference between groups for the FMA.
It is important to consider why the improvements in 
impairment seen with robot-assisted training in the 
RATULS trial did not translate into improved function. 
The RATULS trial provided integrated training with 
all three modules of the MIT-Manus robotic gym 
(shoulder–elbow module; wrist module; and hand 
module), which adapts to participants’ abilities (providing 
more or less assistance as required). The robot-assisted 
training programme did not include grip or pinch 
activities. Participants trained specific movements of 
their affected arm in a spatially controlled manner, but it 
is possible that these were not considered meaningful by 
participants and there might have been insufficient 
guidance for participants about making the best use of 
any reduction in impairment in day-to-day activities. 
Many daily activities involve both upper limbs in bilateral 
(eg, opening a drawer) or bimanual (eg, making a 
sandwich) coordinated action. This could explain why 
robot-assisted training resulted in less favourable out-
comes in self-reported ADL compared with EULT, in 
which training specifically focused on daily activities and 
functional tasks. The improvement in mobility seen after 
EULT would also support this theory, because EULT 
included tasks involving the upper limbs in balance and 
sit-to-stand activities, which were not components of 
robot-assisted training.
The EULT programme was based on goal-orientated 
repetitive functional task practice, which resulted in 
some potentially clinically important benefits over usual 
care and improvements in upper limb impairments that 
were translated into improvement in ADL. This supports 
the conclusions of the 2016 Cochrane review (33 trials, 
1853 participants), which found that repetitive functional 
task practice improved arm function (SMD 0·25 [95% CI 
0·01–0·49]), ADL (SMD 0·28, [0·10–0·45]), and hand 
function (SMD 0·25 [0·00–0·51]).3 The review did not 
include the Graded Repetitive Arm Supplementary 
Program (GRASP) trial,31 which found significant im-
prove ments in upper limb function, grip strength, and 
upper limb use in daily activities. Participants in the 
RATULS trial had more severe upper limb impairment 
than those in the GRASP trial. Delivering EULT as 
group or classroom therapy would lead to a reduction in 
costs. However, the impact of this change on QALYs is 
unknown and should be explored.
It is likely that the pragmatic inclusion criteria led to the 
recruitment of some participants who had little prospect 
of recovery. Approaches that stratify patients into groups 
with differing probabilities of upper limb recovery, such 
as advanced neuroimaging and trans cranial magnetic 
stimulation, have been developed and should be 
considered in future trials to improve the targeting of 
therapies towards participants with the most potential to 
respond.32 Ongoing biomarker research might help in 
patient selection or treatment monitoring of future stroke 
rehabilitation trials.33 Further research is needed to see 
how improvements in upper limb impairment, seen with 
robot-assisted training, can translate into functional gain.
We recruited patients with acute, subacute, and chronic 
stroke in our trial because there was no evidence to 
exclude patients at any stage of recovery. The Cochrane 
systematic review on repetitive task training also found 
no influence of time since stroke on functional 
outcomes.3 Subgroup analyses of the RATULS trial 
showed no clear effect of time since stroke on the 
effectiveness of the interventions.
There is converging evidence that more therapy might 
result in better outcomes,34 but in future, adequately 
powered dose-finding studies of promising interventions, 
tailored to targeted subgroups, are needed, which also 
take into account potential cost-effectiveness. Future trials 
might wish to consider having a co-primary outcome 
measure of a patient-reported outcome measure—eg, 
SIS—as well as one of the standard measures of 
impairment and functional limitation.
In summary, the RATULS trial did not find evidence that 
a robot-assisted training programme using the MIT-
Manus robotic gym improved upper limb function (mea-
sured by ARAT success) after a stroke when compared 
with an EULT programme of the same frequency and 
duration, or usual care. Robot-assisted training led to 
improvement in upper limb impairment (FMA motor 
subscale) compared with usual care but not improve ments 
in upper limb function or ADL. EULT led to improvements 
in upper limb impairment (FMA motor subscale), mobility 
(SIS), and ADL (SIS) compared with usual care at the end 
of the intervention period (at 3 months). Neither robot-
assisted training nor EULT was cost-effective.
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